Drug Approval
BioMarin Going for 2020 Approval of its Hemophilia A Gene Therapy
Pharma's Almanac
PAO-M08-19-NI-026Aug 22, 2019
Positive Opinion
BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older
BioMarin
PR-M03-19-NI-008Mar 04, 2019
Clinical Trials
BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
BioMarin
PR-M06-18-NI-059Jun 18, 2018
Hemophilia
Results of New Gene Therapy Revealed at Hemophilia Meeting
Nice Insight
PAO-M12-17-NI-017Dec 12, 2017
FDA
BioMarin Highlights Advanced Genetic Disease Therapy Pipeline
Nice Insight
PAO-M10-17-NI-035Oct 24, 2017